These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 33515704)
81. Bicyclic Picomolar OGA Inhibitors Enable Chemoproteomic Mapping of Its Endogenous Post-translational Modifications. González-Cuesta M; Sidhu P; Ashmus RA; Males A; Proceviat C; Madden Z; Rogalski JC; Busmann JA; Foster LJ; García Fernández JM; Davies GJ; Ortiz Mellet C; Vocadlo DJ J Am Chem Soc; 2022 Jan; 144(2):832-844. PubMed ID: 34985906 [TBL] [Abstract][Full Text] [Related]
82. The potential role of O-GlcNAc modification in cancer epigenetics. Forma E; Jóźwiak P; Bryś M; Krześlak A Cell Mol Biol Lett; 2014 Sep; 19(3):438-60. PubMed ID: 25141978 [TBL] [Abstract][Full Text] [Related]
84. Proteomic approaches to analyze the dynamic relationships between nucleocytoplasmic protein glycosylation and phosphorylation. Whelan SA; Hart GW Circ Res; 2003 Nov; 93(11):1047-58. PubMed ID: 14645135 [TBL] [Abstract][Full Text] [Related]
85. Hsp90 regulates O-linked β-N-acetylglucosamine transferase: a novel mechanism of modulation of protein O-linked β-N-acetylglucosamine modification in endothelial cells. Zhang F; Snead CM; Catravas JD Am J Physiol Cell Physiol; 2012 Jun; 302(12):C1786-96. PubMed ID: 22496241 [TBL] [Abstract][Full Text] [Related]
86. O-GlcNAcylation promotes non-amyloidogenic processing of amyloid-β protein precursor via inhibition of endocytosis from the plasma membrane. Chun YS; Park Y; Oh HG; Kim TW; Yang HO; Park MK; Chung S J Alzheimers Dis; 2015; 44(1):261-75. PubMed ID: 25208619 [TBL] [Abstract][Full Text] [Related]
87. Insights into O-linked N-acetylglucosamine ([0-9]O-GlcNAc) processing and dynamics through kinetic analysis of O-GlcNAc transferase and O-GlcNAcase activity on protein substrates. Shen DL; Gloster TM; Yuzwa SA; Vocadlo DJ J Biol Chem; 2012 May; 287(19):15395-408. PubMed ID: 22311971 [TBL] [Abstract][Full Text] [Related]
88. Biological Functions and Potential Therapeutic Significance of O-GlcNAcylation in Hepatic Cellular Stress and Liver Diseases. Mao Z; Mu J; Gao Z; Huang S; Chen L Cells; 2024 May; 13(10):. PubMed ID: 38786029 [TBL] [Abstract][Full Text] [Related]
89. Human and rodent temporal lobe epilepsy is characterized by changes in O-GlcNAc homeostasis that can be reversed to dampen epileptiform activity. Sánchez RG; Parrish RR; Rich M; Webb WM; Lockhart RM; Nakao K; Ianov L; Buckingham SC; Broadwater DR; Jenkins A; de Lanerolle NC; Cunningham M; Eid T; Riley K; Lubin FD Neurobiol Dis; 2019 Apr; 124():531-543. PubMed ID: 30625365 [TBL] [Abstract][Full Text] [Related]
90. O-GlcNAcylation in Renal (Patho)Physiology. Silva-Aguiar RP; Peruchetti DB; Pinheiro AAS; Caruso-Neves C; Dias WB Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232558 [TBL] [Abstract][Full Text] [Related]
91. O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-β precursor protein (APP). Jacobsen KT; Iverfeldt K Biochem Biophys Res Commun; 2011 Jan; 404(3):882-6. PubMed ID: 21182826 [TBL] [Abstract][Full Text] [Related]
92. Disrupting the enzyme complex regulating O-GlcNAcylation blocks signaling and development. Whisenhunt TR; Yang X; Bowe DB; Paterson AJ; Van Tine BA; Kudlow JE Glycobiology; 2006 Jun; 16(6):551-63. PubMed ID: 16505006 [TBL] [Abstract][Full Text] [Related]
94. Exploring leukocyte O-GlcNAcylation as a novel diagnostic tool for the earlier detection of type 2 diabetes mellitus. Springhorn C; Matsha TE; Erasmus RT; Essop MF J Clin Endocrinol Metab; 2012 Dec; 97(12):4640-9. PubMed ID: 23066116 [TBL] [Abstract][Full Text] [Related]
95. O-GlcNAcylation under hypoxic conditions and its effects on the blood-retinal barrier in diabetic retinopathy. Xu C; Liu G; Liu X; Wang F Int J Mol Med; 2014 Mar; 33(3):624-32. PubMed ID: 24366041 [TBL] [Abstract][Full Text] [Related]